Filing Flows

Filing Flows › Companies › Cerenome › Cash flow

Cerenome cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$7.6M in Q2 2026 · −$23.5M over twelve months

Operating cash flow−$7.1M
Capital spending−$499K
Free cash flow−$7.6M

Analysis

In Q2 2026, Cerenome generated −$7.1M of operating cash flow and spent $499K on capital projects, leaving free cash flow of −$7.6M. That is $1.8M less than in Q2 2025 (−$5.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$22.2M; the largest uses were operating cash flow ($22.2M), net borrowing (+) / repaid (−) ($1.8M), other investing ($1.6M); besides operations, cash came from other financing ($27.0M); the cash balance rose by $133K.

Operating cash flow was −$7.1M against net income of −$9.0M. The largest differences: payables +$1.3M, stock-based pay +$830K, depreciation & amortization +$137K.

Free cash flow

Cerenome: free cash flow by quarterCerenome: free cash flow by quarter−$3.7MQ3 2024−$1.2MQ4 2024−$6.2MQ1 2025−$5.8MQ2 2025−$2.6MQ3 2025−$6.3MQ4 2025−$7.1MQ1 2026−$7.6MQ2 2026
Operating cash flow less capital spending.
Cerenome: operating cash flow against capital spendingCerenome: operating cash flow against capital spendingOperating cash flowCapital spending−$3.7M$14KQ3 2024−$1.2M$11KQ4 2024−$6.2M$3KQ1 2025−$5.8M$7KQ2 2025−$2.5M$27KQ3 2025−$6.3M$30KQ4 2025−$6.2M$818KQ1 2026−$7.1M$499KQ2 2026
Latest (Q2 2026): Operating cash flow −$7.1M, Capital spending $499K.

Capital allocation, year by year

Cerenome: where the cash came from (up) and went (down), by fiscal yearCerenome: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow −$10.3MFY2021: Net borrowing −$276KFY2021: Shares issued $18.7MFY2021: Asset sales $62K$18.7MFY2021FY2022: Operating cash flow −$13.0MFY2022: Net borrowing −$1.6MFY2022: Shares issued $15.8M$15.8MFY2022FY2023: Operating cash flow −$12.9MFY2023: Net borrowing −$1.6MFY2023: Shares issued $5.5MFY2023: Capital spending −$160KFY2023: Buybacks −$126K$5.5MFY2023FY2024: Operating cash flow −$10.6MFY2024: Net borrowing −$704KFY2024: Shares issued $7.3MFY2024: Capital spending −$146KFY2024: Buybacks −$374K$7.3MFY2024FY2025: Operating cash flow −$20.8MFY2025: Net borrowing −$6.2MFY2025: Shares issued $22.6MFY2025: Asset sales $30KFY2025: Capital spending −$67K$22.6MFY2025
Over these 5 years operating cash flow totalled −$67.4M; the largest uses were operating cash flow ($67.4M) and net borrowing ($10.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$8.6M
Debtnone
Net cash$8.6M
Cash runway4 months

Cerenome is burning cash: its operations consume cash, a free cash flow of −$23.5M a year at the current rate against $8.6M of cash and investments: a runway of about 4 months before any new financing.

Where the cash came from and went

Cerenome: sources (+) and uses (−) of cash, Q2 2026Cerenome: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$7.1MOther investing$5.9MOther financing$1.8MNet borrowing (+) / repaid (−)−$672KCash drawn (+) / kept (−)$656KCapital spending−$499K
Cerenome: sources (+) and uses (−) of cash, TTM to Q2 2026Cerenome: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$27.0MOperating cash flow−$22.2MNet borrowing (+) / repaid (−)−$1.8MOther investing−$1.6MCapital spending−$1.4MCash drawn (+) / kept (−)−$133K

From profit to cash

Cerenome: net income to operating cash flow, Q2 2026Cerenome: net income to operating cash flow, Q2 2026Net income−$9.0MDepreciation & amortization$137KStock-based pay$830KPayables$1.3MPrepaid and other assets$118KOther liabilities−$100KOperating cash flow−$7.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$7.1M−$499K−$672K—$656K−$7.6M
Q1 2026−$6.2M−$818K−$100K—$5.7M−$7.1M
Q4 2025−$6.3M−$30K—$3.0M$4.5M−$6.3M
Q3 2025−$2.5M−$27K—$16.8M−$11.1M−$2.6M
Q2 2025−$5.8M−$7K——$7.6M−$5.8M
Q1 2025−$6.2M−$3K−$7.0M—−$9.8M−$6.2M
Q4 2024−$1.2M−$11K——$1.1M−$1.2M
Q3 2024−$3.7M−$14K——$3.7M−$3.7M

Cerenome: income statement and cash flow

Cerenome, Q2 2026: revenue $411K (-70% year over year). The chart follows the revenue to costs, profit and cash.

Cerenome: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.